Zacks Research Weighs in on Maximus’ Q3 Earnings (NYSE:MMS)

Maximus, Inc. (NYSE:MMS) – Equities researchers at Zacks Research boosted their Q3 2026 earnings estimates for shares of Maximus in a report issued on Thursday, February 26th. Zacks Research analyst Team now forecasts that the health services provider will earn $2.20 per share for the quarter, up from their prior forecast of $2.15. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Maximus’ current full-year earnings is $6.15 per share. Zacks Research also issued estimates for Maximus’ Q4 2026 earnings at $2.28 EPS, FY2026 earnings at $8.34 EPS, Q3 2027 earnings at $2.37 EPS, Q4 2027 earnings at $1.90 EPS, Q1 2028 earnings at $2.00 EPS and FY2028 earnings at $8.94 EPS.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings cut Maximus from a “buy (b)” rating to a “hold (c+)” rating in a research note on Tuesday, February 24th. Wall Street Zen downgraded shares of Maximus from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Maximus Trading Up 3.0%

NYSE:MMS opened at $76.07 on Monday. Maximus has a 12-month low of $63.80 and a 12-month high of $100.00. The firm has a market cap of $4.15 billion, a PE ratio of 11.58 and a beta of 0.59. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.88. The stock has a fifty day moving average price of $86.29 and a 200 day moving average price of $86.26.

Maximus (NYSE:MMS) last posted its quarterly earnings results on Thursday, February 5th. The health services provider reported $1.85 EPS for the quarter, topping the consensus estimate of $1.84 by $0.01. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.37 billion. Maximus had a net margin of 6.92% and a return on equity of 25.30%. The company’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.61 earnings per share. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS.

Maximus Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were given a dividend of $0.33 per share. The ex-dividend date was Friday, February 13th. This represents a $1.32 annualized dividend and a dividend yield of 1.7%. This is a boost from Maximus’s previous quarterly dividend of $0.30. Maximus’s payout ratio is presently 20.09%.

Insider Buying and Selling at Maximus

In other news, CFO David Mutryn bought 1,000 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were acquired at an average price of $75.62 per share, for a total transaction of $75,620.00. Following the completion of the transaction, the chief financial officer owned 40,037 shares of the company’s stock, valued at approximately $3,027,597.94. This trade represents a 2.56% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce Caswell bought 3,175 shares of Maximus stock in a transaction dated Tuesday, February 10th. The stock was purchased at an average cost of $78.45 per share, with a total value of $249,078.75. Following the completion of the acquisition, the chief executive officer directly owned 328,013 shares in the company, valued at approximately $25,732,619.85. The trade was a 0.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 1.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its stake in Maximus by 146.2% in the first quarter. Royal Bank of Canada now owns 19,732 shares of the health services provider’s stock valued at $1,345,000 after buying an additional 11,716 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Maximus by 0.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,476 shares of the health services provider’s stock valued at $2,351,000 after acquiring an additional 221 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Maximus by 7.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 180,690 shares of the health services provider’s stock valued at $12,321,000 after purchasing an additional 11,754 shares during the last quarter. Jane Street Group LLC raised its position in Maximus by 941.2% in the 1st quarter. Jane Street Group LLC now owns 98,273 shares of the health services provider’s stock valued at $6,701,000 after purchasing an additional 88,835 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in Maximus during the 2nd quarter worth $204,000. Institutional investors and hedge funds own 97.21% of the company’s stock.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.